Monitra Health

Monitra Health, operating as Monitra Healthcare Private Limited, develops and operates ambulatory cardiac monitoring products and services centred on its flagship platform, upBeat. The portfolio covers Holter monitoring (continuous portable ECG over 24 hours or longer), external loop recorders that record heart rhythm for up to seven days, and mobile cardiac telemetry that transmits data in real time on a 24x7 basis. The company positions upBeat as a full-stack remote cardiac monitoring platform built for large-scale deployment, used in the diagnosis of unexplained fainting, dizziness and palpitations.

The offering combines a wearable ECG patch with a smartphone application for symptom tagging and a structured clinical reporting workflow. Recordings are sanitised for artefacts and noise, AI-generated annotations and false positives are corrected using proprietary tools, report templates are generated, data is reviewed for clinically relevant events, and ECG strips showing the onset and termination of events are included in the final report. The company states its sensors are of hospital grade and capable of resolving low-amplitude signals such as P waves in ambulatory settings.

Monitra Health reports three pre-clinical studies and one clinical study, with results presented at the European Heart Rhythm Association in April 2022. It holds patents in India and Australia, with applications pending in the US, EU and Canada, and holds ISO-13485 and CDSCO certifications while pursuing CE marking and FDA 510(k) clearance.

Founding story

The company was founded by Ravi Bhogu, who serves as CEO; one company database also lists Aparna Bhogu as a co-founder. The stated premise at founding was that healthcare monitoring should not be cumbersome for patients, with a focus on helping clinicians reach early and accurate diagnoses of cardiac conditions.

Business model

The company operates a B2B2C model, working with healthcare professionals — cardiac electrophysiologists, cardiologists, neurologists and MD physicians — and with medical device channel partners. Devices are prescribed by clinicians and applied at a clinic, hospital or the patient's home; after the monitoring period the device is returned, the recording is analysed through the company's review workflow, and a report is delivered to the prescribing physician.

Revenue is generated from cardiac monitoring devices and associated diagnostic reporting services delivered through clinicians and medical device channel partners. Reported annual revenue was approximately $181 thousand for the year ended 31 March 2023, and a company database lists revenue above ₹5 crore for FY25, an 89.16% increase over the prior fiscal year.

Traction

As of December 2023 the company claimed monitoring of more than 10,000 patients and analysis of over 7.5 billion heartbeats across 720,000 hours of recording. Employee counts reported by company databases range from 39 (April 2024) to 66 (most recent). Company-reported revenue rose to over ₹5 crore in FY25 from the prior year.

Latest developments

Proceeds from the December 2023 pre-Series A round are directed toward domestic expansion, international certifications (CE and FDA 510(k)) and product development for monitoring additional bio-physiological signals. Over a five-year horizon the company has said it plans to extend the platform to monitoring for stroke, high-risk pregnancy, diabetes and newborn care. The founder and the company's work have been covered by Japanese broadcaster NHK.